Unknown

Dataset Information

Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective.


ABSTRACT:

Objectives

The introduction of innovative, high-cost oncology treatments, coupled with mounting budgetary pressures, necessitates value trade-offs across cancer types. Defining value is critical to informing decision-making. A cost-value analysis tool was used to assess relative clinical value from a US perspective using multiple outcome metrics for a variety of metastatic cancers.

Methods

Literature published (January 1, 2000-August 31, 2016) was reviewed to identify outcome metrics for approved treatments for metastatic cancers. Data were extracted or derived for median and mean overall survival (OS), landmark survival rates, and other survival metrics, and compared across treatments vs their respective trial comparators, with and without considering costs.

Results

SUBMITTER: Macaulay R 

PROVIDER: S-EPMC6430994 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature